Coronavirus Update: India Approves Remdesivir, Ex-Biogen Employee Charged
Plus: China Secures Vaccines Manufacturing
• By Scrip Team
Generate a summary of this article
Listen to this article
A former employee of Biogen is officially charged in China for allegedly jeopardizing public health, Wuhan tests 10 million residents, India approves remdesivir.
Guwahati, Assam, India. 2 June. A queue of job applicants at Mahendra Mohan Choudhury Hospital. The country's lockdown has plunged 120m workers into unemployment.
Gilead Sciences Inc. has received the go-ahead in India for Veklury (remdesivir), the antiviral in the forefront as a potential COVID-19 treatment.
The Drugs Controller General of India (DCGI) approved the drug for the treatment of suspected or laboratory confirmed coronavirus disease...
Keep up with the top pharma business news of the week. On the go.
Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.
When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.